In the 4T1 breast cancer mouse model, suppression of KLF4 expression significantly sensitizes breast cancer tumors to olaparib, clearly demonstrating the clinical relevance of KLF4 in synergizing PARP1 in anti‐TNBC breast cancer treatment. Here, KLF4 is linked to breast carcinoma.